FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a method for predicting the risk of developing preeclampsia in pregnant women with diabetes mellitus, where content of 8-iso-PGF2α in peripheral blood serum at 11–14 weeks of pregnancy and if its value is equal to or more than 460.85 pg/ml, a high risk of developing preeclampsia is predicted.
EFFECT: invention provides optimizing the pregnancy management approach before the onset of clinical symptoms of preeclampsia in the first and third trimesters of pregnancy.
1 cl, 1 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE RISK OF PREECLAMPSIA IN PREGNANT WOMEN WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS | 2020 |
|
RU2751139C1 |
| METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 1 DIABETES MELLITUS | 2022 |
|
RU2800717C1 |
| METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 2 DIABETES MELLITUS | 2022 |
|
RU2800716C1 |
| METHOD FOR PREDICTION OF EARLY AND LATE PREECLAMPSIA | 2018 |
|
RU2693412C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING PREECLAMPSIA BASED ON GENETIC TESTING | 2021 |
|
RU2775434C1 |
| METHOD FOR PREDICTING THE RECURRENCE OF EARLY PREECLAMPSIA BY MARKERS OF ENDOTHELIAL DYSFUNCTION | 2022 |
|
RU2795090C1 |
| METHOD FOR PREDICTION OF PREECLAMPSIA IN PREGNANT WOMEN WITH GESTATIONAL DIABETES MELLITUS | 2020 |
|
RU2740852C1 |
| METHOD FOR PREDICTION OF THREATENED MISCARRIAGE BY DETERMINING BLOOD SERUM OF 8-ISOPROSTANE AND 15-HYDROXYEICOSATETRAENOIC ACID IN WOMEN WITH COVID-19 IN THE FIRST TRIMESTER | 2024 |
|
RU2821133C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING PREECLAMPSIA BASED ON MOLECULAR GENETIC ANALYSIS | 2021 |
|
RU2775433C1 |
| METHOD FOR PREECLAMPSIA SEVERITY ASSESSMENT BY RELATIVE CONTENT OF CD16+ MONOCYTES IN PERIPHERAL BLOOD OF PREGNANT WOMEN | 2019 |
|
RU2712228C1 |
